Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company that develops and commercializes medicines, with a focus on rare diseases and patients with limited or no treatment options. Its portfolio includes therapies for sleep disorders, rare epilepsies and cancers, serving patients through… From the company’s description.
In fiscal 2025, Jazz Pharmaceuticals plc reported revenue of $4.27B, up 4.9% from fiscal 2024, and a net loss of $356.15M. Its operating margin was −10.1%, and operations generated $1.36B in cash. Over the twelve months to Jun 30, 2026, revenue was $4.60B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Jazz Pharmaceuticals plc does
In the company’s own words
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company that develops and commercializes medicines, with a focus on rare diseases and patients with limited or no treatment options. Its portfolio includes therapies for sleep disorders, rare epilepsies and cancers, serving patients through healthcare professionals and healthcare systems in the United States and international markets. Major products include Xywav and Xyrem for narcolepsy, Xywav for idiopathic hypersomnia, Epidiolex (marketed as Epidyolex in many countries outside the United States) for seizures associated with rare epilepsies, and the oncology medicines Zepzelca, Rylaze, Ziihera and Modeyso. The company also has research and development programs in rare diseases. Jazz acquired GW Pharmaceuticals in 2021, adding Epidiolex to its portfolio, and acquired Chimerix in 2025, adding Modeyso. Xywav generated $1.657 billion in net product sales in fiscal 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DUBLIN
- Fiscal year end
- December
- CIK
- 1232524
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Jazz Pharmaceuticals plc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Jazz Pharmaceuticals plc · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Jazz Pharmaceuticals plc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Jazz Pharmaceuticals plc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Jazz Pharmaceuticals plc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Jazz Pharmaceuticals plc's last four quarterly filings that the numbers alone won't show?”